Introduction: Depression and cognitive impairment are the most frequent mental disorders in multiple sclerosis (MS) and represent an important cause of morbidity and mortality. The aim of the study was to analyse the main determinants of depression in multiple sclerosis.
Materials and methods: Thirty-two patients with relapsing remitting multiple sclerosis (RRMS), treated with Interferon Beta 1a, without relapses and corticosteroid treatment in the last 30 days, were included in the study. The mean age of the patients was 35.4±9.2 years, M/F ratio 0.33. Depression level was evaluated by the Romanian version of Beck Depression Inventory (BDI) and the cognitive function with Paced Auditory Serial Addition Test 3 (PASAT 3), Symbol Digit Modalities Test (SDMT). The functional status and disability level of the patients were evaluated with Multiple Sclerosis Functional Composite and Expanded Disability Status Scale. In all patients a cerebral MRI with intravenous contrast administration was performed using a 1.5T MRI device.
Results: Twenty-three patients were free of depression (score 1-10), 4 patients presented mild mood disturbance (score 11-16), 3 borderline clinical depression (score 17-20) and 2 moderate depression (score 21-30). The mean BDI score was 8.71±7.16. BDI score correlated significantly with EDSS (R=0.38, p=0.03), PASAT 3 (R=-0.42, p=0.01), SDMT (R=-0.58, p=0.0007), Timed 25-Foot Walk (R=0.43, p=0.01) and 9-Hole Peg Test (R=0.45, p=0.008). From the EDSS functional scores, significant correlations were found with the urinary score (R=0.4, p=0.01) and sensitive score (R=0.49, p=0.004). BDI score correlated significantly with the total number of T2 lesions (R=0.31, p=0.05) while there was no correlation with the number of active lesions.
Conclusions: The main determinants of depression in RRMS patients are the cognitive impairment, the affection of fine hand movements (9-HP), gait impairment (T25FT) and bladder and sensitive dysfunction.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Luzzio C. Multiple Sclerosis.eMedicine.Medscape. Retrieved 11/25/2014 from http://emedicine.medscape.com/article/1146199-overview
2. Reese JP Wienemann G John A Linnemann A Balzer-Geldsetzer M Mueller UO Eienbroker C Tackenberg B Dodel R. Preference-based Health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes; 2013; 11:162.
3. Sahraian MA Etesam F. Cognitive Impairment in Multiple Sclerosis. ZJRMS 2014;16(1):1-7
4. Skokou M Soubasi E GourzisP.Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatricpopulations. ISRN Neurol. 2012;2012:427102. doi: 10.5402/2012/427102.
5. Siegert RJ Abernethy DA. Depression in multiple sclerosis: a review. J NeurolNeurosurg Psychiatry. 2005 Apr;76(4):469-75.
6. Chwastiak L Ehde DM Gibbons LE Sullivan M Bowen JD Kraft GH.Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002 Nov;159(11):1862-8.
7. Niino M Mifune N Kohriyama T Mori M Ohashi T Kawachi I Shimizu Y Fukaura H Nakashima I Kusunoki S Miyamoto K Yoshida K Kanda T Nomura K Yamamura T Yoshii F Kira J Nakane S Yokoyama K Matsui M Miyazaki Y Kikuchi S.Apathy/depression but not subjective fatigue is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol. 2014;14:3. doi: 10.1186/1471-2377-14-3.
8. Langdon DW Amato MP Boringa J Brochet B Foley F Fredrikson S Hamalainen P Hartung HP Krupp L Penner IK Reder AT Benedict RH. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).MultScler. 2012;18(6):891-8. doi: 10.1177/1352458511431076.
9. Beck AT Ward CH Mendelson M Mock J Erbaugh J. An inventory for measuring depression.Arch Gen Psychiatry.1961;4:561-71.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52
11. Parmenter BA Weinstock-Guttman B Garg N Munschauer F Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. MultScler. 2007 Jan;13(1):52-7.
12. Benedict RH Duquin JA Jurgensen S Rudick RA Feitcher J Munschauer FE Panzara MA Weinstock-Guttman B. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008;14(7):940-6. doi: 10.1177/1352458508090923.
13. Cutter GR Baier ML Rudick RA Cookfair DL Fischer JS Petkau J Syndulko K Weinshenker BG Antel JP Confavreux C Ellison GW Lublin F Miller AE Rao SM Reingold S Thompson A Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122:871-882.
14. Fischer JS Rudick RA Cutter GR Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. MultScler 1999;5(4):244-250.
15. Kanner A. Depression in Neurologic Disorders: Diagnosis and Management. August 2012 Wiley-Blackwell
16. Huijbregts SC Kalkers NF de Sonneville LM et al. Cognitive impair ment and decline in different MS subtypes . J Neurol Sci 2006;245:187-194.
17. Whitlock FA Siskind MM. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980;43:861-865.
18. Schubert DS Foliart RH. Increased de pression in multiple sclerosis patients. A meta - analysis. Psychosomatics 1993;34:124-130.
19. Sadovnick AD Remick RA Allen J et al. Depression and multiple sclerosis. Neurology 1996;46:628-632.
20. Joffe RT Lippert GP Gray TA et al. Mood disorder and multiple sclerosis . Arch Neurol 1987;44:376-378.
21. Patten SB Beck CA Williams JV et al. Major depression in multiple sclerosis: a population - based perspective. Neurology 2003;61:1524-1527.
23. Rabkin JG Albert SM Del Bene ML et al. Prevalence of depressive disorders and change over time in late - stage ALS. Neurology 2005;65:62-67.
24. Gilchrist AC Creed FH. Depression cognitive impair ment and social stress in multiple sclerosis. J Psychosom Res 1994. 38:193-201.
25. Lobentanz IS Asenbaum S Vass K et al. Factors influencing quality of life in multiple sclerosis patients: disability depressive mood fatigue and sleep quality. Acta Neurol Scand 2004;110:6 - 13.
26. Janssens AC van Doorn PA de Boer JB et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003;9:397-403.
27. Galeazzi GM Ferrari S Giaroli G et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005;26:255-262.
28. Gay MC Vrignaud P Garitte C et al. Predictors of depression in multiple sclerosis patients. Acta Neurol Scand 2010;121:161-170.
29. Dahl OP Stordal E Lydersen S et al. Anxiety and depression in multiple sclerosis. A comparative population - based study in Nord - Trondelag County Norway. Mult Scler 2009;15:1495-1501.
30. Beal CC Stuifbergen AK Brown A. Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatr Nurs 2007;21:181-191.
31. Zabad RK Patten SB Metz LM. The association of depression with disease course in multiple sclerosis. Neurology. 2005;64:359-360.
32. Kessler RC McGonagle KA Swartz M et al. Sex and depression in the National Comorbidity Survey: lifetime prevalence chronicity and recurrence. J Affect Disord 1993;29:85-96.
33. Weissman MM Bland RC Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-299.
34. Beiske AG Svensson E Sandanger I et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol 2008;15:239-245.
35. Kneebone II Dunmore EC Evans E. Symptoms of depression in older adults with multiple sclerosis (MS): comparison with a matched sample of younger adults. Aging Ment Health 2003;7:182-185.
36. Benedict RH Amato MP Boringa J et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol 2012;16:12:55.
37. Amato MP Portaccio E Goretti B et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler 2010;16:1474-1482.
38. Amato MP Portaccio E Stromillo ML et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008;71:632-638.
39. Filippi M Rocca MA Benedict RH et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010;75:2121-2128.
40. Wallin MT Wilken JA Turner AP Williams RM Kane R. Depression and multiple sclerosis: Review of a lethal combination. J Rehabil Res Dev 2006;43:45-62.
41. Maor Y Olmer L Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients--the role of depression. Mult Scler 2001;7:131-135.
42. Krupp LB Sliwinski M Masur DM Friedberg F Coyle PK. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol 1994;51:705-710.
43. Kenealy PM Beaumont JG Lintern TC Murrell RC. Autobiographical memory in advanced multiple sclerosis: assessment of episodic and personal semantic memory across three time spans. J Int Neuropsychol Soc 2002;8:855-860.
44. Feinstein A Roy P Lobaugh N Feinstein K O’Connor P Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586-590